An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.

by David J Pinato, Chara Stavraka, Michael J Flynn, Martin D Forster, Séan M O'Cathail, Michael J Seckl, Rebecca S Kristeleit, David Olmos, Samantha J Turnbull, Sarah P Blagden
Published 2014-01-01